- Trial phase
- Approved
- Time to market
- Already on the market, first approved April 2017; Austedo XR approved February 2023
- Why 4/10
- Austedo is already approved and commercially marketed with no pending binary catalyst (PDUFA or pivotal readout) in the next ~12 months. Per the impact score rubric, an approved drug with no imminent new regulatory decision scores 3-5, the binary events (initial FDA approvals in 2017, XR approval in 2023) have already passed.
Austedo is a mature, approved revenue driver for Teva, commercial execution and growth trajectory matter more than any single catalyst. Watch Teva's quarterly innovative brand revenue growth rate (43% LC YoY in H1 2026) and any label-expansion trial updates for downward drift potential, as the binary approval catalysts are years past.
Price Chart
Executive Summary
Austedo (deutetrabenazine) is Teva Pharmaceutical's already-approved, commercial-stage VMAT2 inhibitor for treating tardive dyskinesia and Huntington's disease chorea. First approved by the FDA in April 2017, with an extended-release version (Austedo XR) approved in February 2023. Austedo is Teva's largest innovative brand: H1 2026 revenue was approximately $696M, with the combined innovative brand portfolio (Austedo, Ajovy, Uzedy) growing 43% YoY in local currency. Teva raised its 2026 revenue outlook for these three brands to ~$3.7B combined. With no pending PDUFA or pivotal readout, Austedo's stock-moving binary catalyst has already passed, its value to shareholders is commercial execution and revenue growth within a diversified large-cap pharma ($16.5-16.85B total revenue, $36.9B market cap).
How It Works
Austedo is a VMAT2 inhibitor, it reduces the amount of certain chemicals (dopamine) in the brain that cause uncontrolled movements. It is a deuterated (chemically modified for slower breakdown) version of the older drug tetrabenazine, allowing for less frequent dosing and potentially fewer side effects.
Trial Status
Austedo and Austedo XR are both FDA-approved and commercially available. The pivotal trials (ARM-TD for tardive dyskinesia, FIRST-HD for Huntington's chorea) completed years ago. No active pivotal-stage trials for new indications were found in the SecBot database.
The Two-Sided Case
Upcoming Catalysts
- No FDA PDUFA dates or pivotal readouts scheduled for Austedo specifically; commercial revenue growth trajectory is the key ongoing metric.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K TEVA ·Originating report